News Ipsen buys ImCheck, adding mid-stage leukaemia drug Ipsen has agreed to buy ImCheck and its anti-BTN3A antibody for acute myeloid leukaemia in a deal that could be worth up to €1bn.
News Nature: "Sidewinder" tech a leap forward in DNA synthesis A new technology developed at Cal-Tech represents a breakthrough in DNA synthesis, essentially allowing de novo sequence creation.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
